Post Resch Tallon Group’s AbbVie ABBV Stock Holding History

Post Resch Tallon Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$419K	Hold	1,664	–	–	0.29%	62
2026 Q1	$366K	Hold	1,664	–	–	0.3%	64
2025 Q4	$380K	Sell	1,664 -57	-3%	-$13K	0.32%	56
2025 Q3	$398K	Hold	1,721	–	–	0.35%	53
2025 Q2	$319K	Hold	1,721	–	–	0.31%	59
2025 Q1	$356K	Hold	1,721	–	–	0.36%	53
2024 Q4	$309K	Buy	+1,721	New	+$316K	0.3%	59

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Post Resch Tallon Group's ABBV Position: Q2 2026 in Review

Post Resch Tallon Group held its AbbVie (ABBV) position steady in Q2 2026 at 1,664 shares worth $419K. The position accounts for 0.29% of the portfolio, ranked #62.

Post Resch Tallon Group first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Post Resch Tallon Group held 1,664 shares of AbbVie worth $419K as of Q2 2026.
Post Resch Tallon Group left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.29% of Post Resch Tallon Group's portfolio in Q2 2026, its #62 holding.
Post Resch Tallon Group first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Post Resch Tallon Group's 13F filing for Q2 2026, filed 7 Jul 2026.